<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; labyrinth</title>
	<atom:link href="http://www.tapanray.in/tag/labyrinth/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Is India A Success Story With Biosimilar Drugs?</title>
		<link>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-india-a-success-story-with-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 25 Feb 2019 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pathways]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[revenue]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[uncertainty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9422</guid>
		<description><![CDATA[How Indian generic companies are expanding, if not shifting their business focus on biosimilar and complex generic drugs, may be a current trend of general discourse &#8211; but the initiative is not a current one. This journey commenced decades ago &#8230; <a href="http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patent Expiry No Longer End of The Road</title>
		<link>http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-expiry-no-longer-end-of-the-road</link>
		<comments>http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/#comments</comments>
		<pubDate>Sun, 03 Dec 2017 23:30:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Adalimumab]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end]]></category>
		<category><![CDATA[exemptia]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Infliximab]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[MabThera]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Remicade]]></category>
		<category><![CDATA[Rituxan]]></category>
		<category><![CDATA[Rituximab]]></category>
		<category><![CDATA[Road]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8600</guid>
		<description><![CDATA[Who says that the phenomenal success of blockbuster drugs is mostly eaten away by  ‘look-alikes’ of the same, immediately after respective patent expiry? It doesn’t seem to be so any longer, not anymore! Several examples will vindicate this emerging trend. &#8230; <a href="http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The New Drug Policy is languishing in a labyrinth</title>
		<link>http://www.tapanray.in/the-new-drug-policy-is-languishing-in-a-labyrinth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-new-drug-policy-is-languishing-in-a-labyrinth</link>
		<comments>http://www.tapanray.in/the-new-drug-policy-is-languishing-in-a-labyrinth/#comments</comments>
		<pubDate>Mon, 02 Apr 2012 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[DPCO95]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[languishing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NLEM2011]]></category>
		<category><![CDATA[NPPP 2011]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=113</guid>
		<description><![CDATA[Drug Price Control has remained the key feature of all Drug Policies of India, since their inception in early 70’s. Most of these policies continued to remain behind their times consistently, without any exception. That said, the Drug Policy 1994 &#8230; <a href="http://www.tapanray.in/the-new-drug-policy-is-languishing-in-a-labyrinth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-new-drug-policy-is-languishing-in-a-labyrinth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Healthcare Industry of India: Being catapulted from a labyrinth to an accelerated growth trajectory</title>
		<link>http://www.tapanray.in/healthcare-industry-of-india-being-catapulted-from-a-labyrinth-to-an-accelerated-growth-trajectory/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=healthcare-industry-of-india-being-catapulted-from-a-labyrinth-to-an-accelerated-growth-trajectory</link>
		<comments>http://www.tapanray.in/healthcare-industry-of-india-being-catapulted-from-a-labyrinth-to-an-accelerated-growth-trajectory/#comments</comments>
		<pubDate>Mon, 12 Mar 2012 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accelerated]]></category>
		<category><![CDATA[Being]]></category>
		<category><![CDATA[catapulted]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[GDP]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trajectory]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=122</guid>
		<description><![CDATA[As reported by the &#8216;World Health Statistics 2011&#8242;, India spends around 4.2 percent of its Gross Domestic Product (GDP) on health, which is quite comparable with other BRIC countries like, China and Russia.This has been possible mainly due to increasing &#8230; <a href="http://www.tapanray.in/healthcare-industry-of-india-being-catapulted-from-a-labyrinth-to-an-accelerated-growth-trajectory/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/healthcare-industry-of-india-being-catapulted-from-a-labyrinth-to-an-accelerated-growth-trajectory/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
